Orca-T

Phase I Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1
Enrollment
24 patients (estimated)
Sponsors
Stanford University Cancer Institute (Palo Alto)
Collaborators
Orca Biosystems, Inc.
Tags
Allogeneic Stem Cell Transplant, T Cell (Allogeneic)
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1981
NCT Identifier
NCT06551584

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.